<DOC>
	<DOC>NCT02111954</DOC>
	<brief_summary>Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new PET/CT radiotracer aiming at giving complementary information : more precise images and early localisation of recurrence to standard imaging</brief_summary>
	<brief_title>Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients</brief_title>
	<detailed_description>Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will be proposed to participate to the present study. After signing the patient informed consent, both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval. No adverse events are expected.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age : adult patients Karnofsky : â‰¥ 80% Patients with histologically proven prostate cancer for whom 18Ffluocholine PET/CT is indicated for primary cancer staging, or for recurrence with increase of blood PSA. In order to provide a detection probability of 30% or more, a blood PSA 0.5 ng / ml or more in post initial curative intent surgery will be required. Signed informed consent. Lack of discernment to sign the consent form Age &lt;18 years Patient under hormonal treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>primary</keyword>
	<keyword>recurrence</keyword>
	<keyword>F-18-FCH PET/CT</keyword>
	<keyword>Ga-68-NODAGA-MJ9 PET/CT</keyword>
</DOC>